Organigram reports Q1 revenue C$42.7M vs. C$36.5M last year

Reports Q1 adjusted EBITDA1 C$1.4M vs. C$0.1M in the prior year period. “This is an exciting time for Organigram (OGI) as we kick off Fiscal 2025 as Canada’s largest recreational cannabis company by market share,” said Beena Goldenberg, CEO. “Our strategic priorities for the fiscal year focus on integrating Motif to maximize operational synergies, continuing to expand our presence in international markets, and driving even more innovation-both in our product portfolio to delight our consumers, and also within our operations to enhance value for our shareholders.” “Organigram’s year-over-year performance highlights the long-term benefits of our investments in efficiency, disciplined capital deployment, and market-leading research and innovation,” said Greg Guyatt, CFO. “With one of the strongest balance sheets in the industry, we look forward to showcasing the full impact of our consolidated Organigram-Motif earnings in Q2. In addition, the anticipated C$41.5M final BAT follow-on investment tranche, which is expected to close in late February, further strengthens our balance sheet and fuels our international expansion goals.”